leukocytes during stable COPD are associated with poor outcomes. [14] [15] [16] [17] Thus, these biomarkers may also be associated with an increased risk of having exacerbations. In this study, we tested the hypothesis that elevated levels of inflammatory biomarkers in individuals with stable COPD are associated with an increased risk of having exacerbations.
METHODS
We studied age-stratified, randomly selected white individuals from 2 similar general population studies, essentially conducted by the same investigators and using identical methods: the 2001-2003 examination of the Copenhagen City Heart Study and the 2003-2008 examination of the Copenhagen General Population Study. [18] [19] [20] Number and age distributions of individuals invited to participate, all participants, and participating individuals with COPD in the 2 studies are shown in eFigure 1 (available at http: //www.jama.com). Random selection was conducted at invitation based on the Danish Central Person Register number given to all persons living in Denmark, that is, prior to ascertainment of COPD diagnosis. Both studies were approved by Herlev Hospital and a Danish ethics committee and were conducted according to the Declaration of Helsinki. Written informed consent was obtained from all participants. There was no overlap of individuals between the 2 studies. In both studies, all participants filled out a questionnaire reviewed by an examiner at attendance, had spirometry performed, and had blood samples drawn. The current study selected a subgroup of individuals with COPD for further studies. The participants with COPD in the 2 studies were analyzed as 1 collective cohort to obtain maximal statistical power.
Spirometry
Forced expiratory volume in 1 second (FEV 1 ) and forced vital capacity (FVC) were determined without inhalation of a bronchodilator using a dry wedge spirometer (Vitalograph; Maids Moreton) in the Copenhagen City Heart Study and in the first 14 624 participants of the Copenhagen General Population Study. For the remaining participants of the Copenhagen General Population Study, an EasyOne Spirometer (ndd Medizintechnik) was used. Reference values for FEV 1 were internally derived for men and women separately in a subsample of healthy neversmokers using linear regression with age and height as covariates. In stratified analyses, participants were grouped according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 1 through 4 for airflow limitation and the recent GOLD grades A through D for assessing both symptoms and risk. 2 Breathlessness was assessed using the Medical Research Council questionnaire, and history of frequent exacerbations was defined as having had 2 or more exacerbations in the year before examination. Classification criteria for GOLD grades are shown in eTable 1. Distributions of FEV 1 percent predicted according to GOLD grades are shown in eFigure 2. In the analyses presented, GOLD grades A-B, C-D, 1-2, and 3-4 were combined to obtain maximum statistical power; however, if analyzed separately, the results were largely similar but attenuated in higher GOLD grades.
Inflammatory Biomarkers
Plasma levels of high-sensitivity CRP and fibrinogen and whole blood leukocyte count in both studies were measured using standard hospital assays at a central laboratory at Herlev Hospital. We chose these 3 biomarkers because they are widely available and commonly used to monitor disease in patients with COPD. As in our previous study, 17 biomarkers were analyzed in combination defined as high or low according to cut points. Although such categorization may lead to loss of information compared with using the biomarkers as continuous variables, we used cut points because they are simple and clinically useful. Levels of CRP were categorized using the cut point 3 mg/L, a cut point that previously has been used by us and others in cardiovascular/pulmonary medicine. 15, 20, 21 We next defined equivalent cut points for fibrinogen and leukocyte count, 14 mol/L for fibrinogen and 9 ϫ10 9 /L for leukocyte count, so that the numbers in each of the low and high groups for each biomarker were roughly the same. If each biomarker was analyzed separately or in any combination with one other biomarker, results were attenuated but largely similar to those presented.
Exacerbations
An exacerbation of COPD was defined as a short-course treatment with oral corticosteroids alone or in combination with an antibiotic or as a hospital admission due to COPD. This information was collected for each individual by linking our database to 2 national registries: the Danish Registry of Medicinal Product Statistics, which contains information on all prescriptions dispensed in all Danish pharmacies, and the Danish National Patient Registry covering all hospital contacts in Denmark. We identified treatment with oral corticosteroids (H02AB) and antibiotics (J01) using the Anatomic Therapeutic Chemical code 22 and diagnoses of COPD (DJ41-44) using the World Health Organization International Classification of Diseases code. 23 This ascertainment seems valid because short-course treatments of oral corticosteroids are not used for other conditions in patients with COPD and because administrative data on hospital admissions in Denmark have shown a high validity and adequate completeness. 24 Treatments with oral corticosteroids or oral corticosteroids in combination with antibiotics and hospital admissions had to be a minimum 4 weeks apart to be considered separate exacerbations. Frequent exacerbations were defined as 2 or more exacerbations less than 1 year apart. A history of frequent exacerbations was defined as 2 or more exacerbations in the year before examination. For each participant, exacerbations were recorded 1 year prior to the examina-tion date and forward until the end of follow-up in August 2010. Deaths due to respiratory failure without prior hospitalization were not captured in the Danish National Patient Registry; however, we expect these to be rare in Denmark where hospitalization is free of charge.
Covariates
Body mass index was calculated as weight in kilograms divided by height in meters squared. Participants were categorized as current smokers, former smokers, or never smokers. Any inhaled medication was any prescription of inhaled short-and long-lasting ␤ 2 -agonists, anticholinergics, corticosteroids, or combination products in the year prior to examination. (eTable 2 lists the number of participants using each type of inhaled medication and corresponding Anatomic Therapeutic Chemical codes.)
Statistical Analysis
We used Stata/SE version 12.0. A 2-sided P value less than .05 was considered significant. First, we analyzed risk of having frequent exacerbations during the first year of follow-up using logistic regression. Models were multivariable adjusted for age, sex, FEV 1 percent predicted, smoking, use of any inhaled medication, and body mass index. One model was in addition adjusted for history of frequent exacerbations and time since most recent prior exacerbation. Assessment of model fit was by Hosmer-Lemeshow test. Second, we analyzed risk of having at least 1 exacerbation and risk of having frequent exacerbations with maximum follow-up time using Cox proportional hazards regression models with delayed entry at examination (left truncation). The assumption of proportional hazards was tested with the Lin, Wei, and Ying score process test. 25 Misspecifications of the functional form of the covariates were tested by plotting the continuous covariates against the cumulative residuals and comparing them with random realizations under the model. Follow-up time for each participant began at study entry and ended at event, death (n = 744), or August 2010, whichever came first; we did not lose track of any individual.
Multivariable models were adjusted for age (as time scale), sex, FEV 1 percent predicted, smoking, use of any inhaled medication, body mass index, history of frequent exacerbations, and time since most recent prior exacerbation. The added discriminative power offered by the addition of inflammatory biomarkers to a basic model with clinical characteristics was analyzed using area under the curve, Harrell C index, 26 and the net reclassification index. 27 Positive and negative predictive values were calculated. For test for trend of risk estimates, groups based on increasing levels of CRP and fibrinogen and leukocyte count were coded 0, 1, 2, etc. Test of interaction in the Cox model was performed by introducing a 2-factor interaction term, and P values were by likelihood ratio test for comparing models with and without the interaction term. Finally, absolute 1-year, 3-year, and 5-year risk by groups of the 3 biomarkers was estimated using the regression coefficients from a Poisson regression model. 28 Because we only included individuals from the cohort with complete information on inflammatory biomarkers and covariates for adjustments, we had no individuals with missing values.
RESULTS
Among 5919 participants of the Copenhagen City Heart Study and 55 731 participants of the Copenhagen General Population Study, 8020 individuals had COPD, defined as a ratio between FEV 1 and FVC below 0.7. Aiming to avoid misclassification with asthma, we excluded individuals with self-reported asthma (n=1198) and individuals younger than 40 years of age (n=196). Also, individuals with missing values for covariates (n=3) or measurements of any of the 3 biomarkers (n=49) were excluded, leaving 6574 individuals available for analyses. Baseline characteristics of the 6574 participants with stable COPD stratified by GOLD grades and history of frequent exacerbationsareshownintheTABLEand eTables 3 through 5. During a median 4 years (interquartile range, 2.4-5.5) of follow-up time, 3083 exacerbations were recorded (mean, 0.5/participant). Among all 6574 participants, 244 individuals (4%) had 1 or more exacerbations in the year prior to examination, and 85 (1%) had their most recent exacerbation within 2 months of the examination date (eFigure 3).
Frequent Exacerbations During First Year of Follow-up
During the first year of follow-up time, 129 individuals had frequent exacerbations (Ն2). The number of individuals with frequent exacerbations increased stepwise according to groups of inflammatory biomarkers (FIGURE 1). Numbers of events per 1000 personyears were 17 (95% CI, 12-25) for individuals with 1 high biomarker (n=1831), 32 (95% CI, 24-46) for individuals with 2 high biomarkers (n=1066), and 81 (95% CI, 59-120) for individuals with 3 high biomarkers (n = 384), compared with 9 (95% CI, 6.6-13) for individuals with no elevated biomarkers (n = 3293). Corresponding multivariable-adjusted odds ratios for having frequent exacerbations were 1.5 (95% CI, 0.9-2.6), 2.6 (95% CI, 1.6-4.3), and 6.4 (95% CI, 3.8-11) (trend: P=3ϫ10
Ϫ11
). When including adjustment for history of frequent exacerbations and time since most recent prior exacerbation, corresponding odds ratios were 1.2 (95% CI, 0.7-2.2), 1.7 (95% CI, 0.9-3.2), and 3.7 (95% CI, 1.9-7.4), respectively (trend: P=2ϫ 10 Ϫ5 ).
Exacerbations During Maximum Follow-up Time
During follow-up time, 931 individuals had at least 1 exacerbation. Among these individuals, 423 had frequent exacerbations (Ն2 less than 1 year apart). Risk of having at least 1 exacerbation and risk of having frequent exacerbations increased stepwise from none through 3 high inflammatory biomarkers (FIGURE 2). Multivariable-adjusted hazard ratios for having at least 1 exacer- ). Corresponding hazard ratios for having frequent exacerbations Plasma C-reactive protein and fibrinogen and blood leukocyte count were defined as high or low according to cut points of 3 mg/L, 14 mol/L, and 9 ϫ10 9 /L, respectively. Models were multivariable adjusted for age (as time scale), sex, forced expiratory volume in 1 second percent predicted, smoking, use of any inhaled medication, body mass index, history of frequent exacerbations, and time since most recent prior exacerbation. For having Ն1 exacerbation, trend P=2ϫ10
Ϫ7
; for having frequent exacerbations, trend P=1ϫ10
Ϫ8
. COPD indicates chronic obstructive pulmonary disease; HR, hazard ratio.
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were 1.4 (95% CI, 1.1-1.8), 1.6 (95% CI, 1.3-2.2), and 2.5 (95% CI, 1.8-3.4), respectively (trend: P =1ϫ10 Ϫ8 ). All models included other covariates and also adjustment for history of frequent exacerbations and time since most recent prior exacerbation.
Model Accuracy and Predictive Values
Discrimination and predictive values of the 3 inflammatory biomarkers for risk of frequent exacerbations are shown in eTable 6. The addition of inflammatory biomarkers to a basic model including age, sex, FEV 1 percent predicted, smoking, use of any inhaled medication, body mass index, history of previous exacerbations, and time since most recent prior exacerbation improved the C statistics from 0.71 to 0.73 (comparison: P =9ϫ10 Ϫ5 ). Positive and negative predictive values for 3 high biomarkers vs none for frequent exacerbations were 8% and 99% during the first year of follow-up and 18% and 96% during maximum followup, respectively. For comparison, positive and negative predictive values for history vs no history of frequent exacerbations were 58% and 99% during the first year of follow-up and 72% and 95% during maximum follow-up time, respectively. For frequent exacerbations during the first year of follow-up, adding the inflammatory biomarkers to the basic model yielded a combined net reclassification index of 40% (95% CI, 22%-57%; P=8ϫ10 Ϫ6 ) (eFigure 4).
Sensitivity Analyses
When the models shown in Figure 2 were also adjusted for number of previous exacerbations on a continuous scale, or individuals with exacerbations in the first year of follow-up were excluded, the results were similar to those presented (eFigures 5 and 6). Also, in the analyses stratified according to GOLD grades A-D, history of frequent exacerbations, or GOLD grades 1-4, risks of having at least 1 exacerbation or risks of having frequent exacerbations were similar in all strata (FIGURE 3) (test of interaction: all PϾ.06). The wider confidence intervals for risk estimates for those with GOLD C-D (n=558) vs A-B (n = 6016), for those with a history of frequent exacerbations (n=127) vs no history (n=6447), and for those with GOLD 3-4 (n = 465) vs GOLD 1-2 (n = 6109) are explained by lower statistical power in the former vs latter strata. Also, in analyses stratified by smoking habits (never, former, current), results were similar in former and current smokers but attenuated in never smokers (eFigure 7). Furthermore, when the 2 studies were analyzed separately, results were similar when comparing individuals with 3 high biomarkers with individuals who had no elevated biomarkers.
Absolute Risk of Frequent Exacerbations
There was a stepwise increase in the absolute 1-year, 3-year, and 5-year risk of having frequent exacerbations from none through 3 high inflammatory biomarkers, in all strata of GOLD grades A-D, history of frequent exacerbations, and GOLD grades 1-4 (FIGURE 4). The highest 5-year absolute risks of having frequent exacerbations in those with 3 high biomarkers (vs no high biomarkers) were 62% (vs 24%) for those with GOLD grades C-D (n=558), 98% (vs 64%) in those with a history of frequent exacerbations (n=127), and 52% (vs 15%) for those with GOLD grades 3-4 (n = 465).
DISCUSSION
The principal finding of this study is that simultaneously elevated levels of CRP, fibrinogen, and leukocytes were associated with increased risk of frequent exacerbations in individuals with stable COPD. Risk of having frequent exacerbations was increased approximately 4-fold in the first year of follow-up and 3-fold using maximum follow-up time in individuals with 3 high inflammatory biomarkers compared with individuals who had no elevated biomarkers. Importantly, relative risk estimates were consistent even in those with milder COPD and in those with no history of frequent exacerbations, suggesting that these biomarkers provide additional information to the latest GOLD 2011 grading. 2 These findings may enable clinicians using absolute risk estimates to provide a more stratified management focusing on exacerbation prevention and are yet another step toward personalized medicine in COPD.
A subgroup of patients with COPD have increased levels of inflammatory biomarkers during stable conditions, 13 and we found that these individuals seem particularly prone to developing future exacerbations. One explanation could be that high levels of inflammatory biomarkers reflect bacterial colonization or latent viral infections persisting in airway epithelial after a previous exacerbation, 10, 29 which is an important predictor for subsequent exacerbations. 9 Also, the degree of lung inflammation and thus disease activity is another important factor. 9 However, in this study, the association was independent of previous exacerbations and degree of airflow limitation, suggesting that low-grade systemic inflammation in itself may have a negative effect on the immunological response to airborne pathogens increasing exacerbation susceptibility. In human experimental models of virus-induced exacerbations, patients with COPD had impaired production of interferon-␤ by alveolar macrophages compared with healthy controls. 30 Also, the presence of systemic low-grade inflammation could hypothetically have a negative synergistic effect on innate cytokine response, leading to an insufficient immune response, but the exact biological mechanism behind the present observations remains unclear.
Previous studies on inflammatory biomarkers and COPD exacerbations are scarce, but the studies that have been conducted so far support our findings. 9, 16, 31 A study from the ECLIPSE cohort found elevated levels of CRP and fibrinogen and leukocyte count to be associated with the occurrence of exacerbations in the first year of follow-up in univariate analyses. 9 How-ever, after multivariable adjustment including previous exacerbations, only the association found for elevated leukocyte count remained statistically significant.
Another study found elevated levels of fibrinogen to be an independent risk factor for COPD exacerbation, 31 but in that study, all participants had a history of previous exacerbations, which may have confounded results. It seems that by combining elevated levels of several inflammatory biomarkers, as done by us, the association with exacerbations becomes more robust. In line with this, another recent study measured 6 inflammatory biomarkers at baseline and found that COPD patients with elevated levels of 2 or more inflammatory biomarkers persisting at least 1 year after follow-up had increased allcause mortality and exacerbation frequency, when compared with controls. 16 Also, addition of several biomarkers to established clinical measures in COPD increased the capacity to predict mortality compared with adding a single biomarker. 32 In line with these findings, the addition of inflammatory biomarkers in our study increased the capacity to predict frequent exacerbations, but the increment in the C statistics was limited. However, obtaining increases in Harrell C index for a new model is very difficult when strong risk factors such as FEV 1 percent predicted and history of frequent exacerbations are already included in the basic model. 33 Thus, the magnitude of the increase in C statistics is difficult to translate into a clinical value, as is the increase in continuous net reclassifica- Plasma C-reactive protein and fibrinogen and blood leukocyte count were defined as high or low according to cut points of 3 mg/L, 14 mol/L, and 9 ϫ10 9 /L, respectively. Models were multivariable adjusted for age (as time scale), sex, forced expiratory volume in 1 second percent predicted, smoking, use of any inhaled medication, body mass index, history of frequent exacerbations, and time since most recent prior exacerbation. For Ն1 exacerbation and for frequent exacerbations, respectively, trend P values were as follows: GOLD grades A-B, P=2ϫ10
Ϫ6 for both; GOLD grades C-D, P=.04 and P=6ϫ10
Ϫ3
; no history of frequent exacerbations, P=4ϫ10 Ϫ8 and P=1ϫ10
Ϫ6
; history of frequent exacerbations, P=.32 and P=.07; GOLD grades 1-2, P=6ϫ10 Ϫ7 and P=4ϫ10
Ϫ8
; GOLD grades 3-4, P=5ϫ10 Ϫ3 and P=8 ϫ10
Ϫ3
. COPD indicates chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HR, hazard ratio. tion index, and the utility of the inflammatory biomarkers in a clinical setting need to be evaluated in future studies. Nevertheless, the current absolute 1-year, 3-year, and 5-year absolute risks of frequent exacerbations are directly applicable to clinical practice, as are the positive and negative predictive values. To our knowledge, our observational study is the first to show that elevated levels of 3 commonly measured inflammatory biomarkers combined were associated with increased risk of frequent exacerbations, even in patients without previous exacerbations.
A strength of this large study on inflammatory biomarkers and exacerbations in COPD is that we recruited participants from the general population. Our prospective design and registrybased definition of exacerbations with 100% follow-up avoiding investigator bias is another major strength. Limitations include that we only had prebronchodilator measurements available and that we defined COPD based on airflow limitation alone. Also, as in other epidemiological studies, our findings are affected by selection bias due to possible overrepresentation of relatively healthy patients with COPD. Compared with studies recruiting in a hospital setting, there are fewer participants with severe COPD, fewer users of inhaled medication, and relatively low numbers of patients experiencing frequent exacerbations, all of which will reduce the statistical power to detect an association in those with severe COPD and previous exacerbations. However, this would tend to draw the results in a direction toward the null hypothesis and cannot explain our positive results.
Another potential limitation is the changes in treatment of COPD over the study period. Over time, there has been a gradual increase in the use of tiotropium and combination therapy with inhaled corticoids and long-acting ␤ 2 -agonists in maintenance treatment. However, this is not likely to have influenced our results to a major extent, because tiotropium does not affect levels of inflammatory biomarkers 34 and because the use of inhaled corticosteroids is relatively rare in populationbased cohorts. Finally, although we have previously published data on reasonable stability of CRP and fibrinogen levels over 10 years in individuals with COPD ( Figure E1 in the online data supplement of Thomsen et al 17 ), we do not have similar data for leukocyte count; however, a previous study found low variability in levels of fibrinogen and leukocytes in patients with COPD over time, 35 and this is likely to be similar in our cohort.
Until recently, the most important criterion for therapy guiding in COPD has been the degree of airflow limitation. The findings from the ECLIPSE study, 9 among others, have led to a new classification of COPD, 2 enabling identification of more individuals at risk of frequent exacerbations and disease progression than the previous classification. 36 A recent study found pulmonary artery enlargement on chest computed tomography to be an independent predictor of exacerbations. 37 However, our study provides novel information that may lead to a simpler assessment using measurements of inflammatory biomarkers in individuals with stable COPD to further stratify preventive therapies based on absolute risk of frequent exacerbations. The potential benefits of such stratification should be tested in future clinical trials that could include drugs of particular current interest, such as macrolides 38 or statins. 39 In conclusion, simultaneously elevated levels of CRP and fibrinogen and leukocyte count were associated with increased risk of exacerbations in stable COPD, even for individuals with milder COPD and for those without previous exacerbations. Further investigation is needed to determine the clinical value of these biomarkers for risk stratification.
